Cagrilintide
Long-acting amylin analogue in clinical development by Novo Nordisk. Combined with semaglutide as CagriSema; produces additive weight loss beyond GLP-1 receptor engagement alone.
0 anonymous reports
Also known as:
cagricagrisema ingredientamylin analogue
browse topics:
community guides:
No reports found.
Community Q&A
- What is cagrilintide and what does it do?
- Community accounts describe cagrilintide as the amylin component of CagriSema — the combination of cagrilintide plus semaglutide being tested for superior weight loss. Amylin slows gastric emptying and reduces appetite through CNS pathways distinct from GLP-1. Accounts from early adopters who sourced it describe adding cagrilintide to an existing semaglutide protocol for additional appetite suppression, describing it as meaningfully additive.
- CagriSema vs tirzepatide — which produces more weight loss?
- Community accounts are split because trial data and community experience is still accumulating for CagriSema. Early accounts describe weight loss comparable to or exceeding tirzepatide at the equivalent stage of protocol. The mechanism difference described: tirzepatide adds GIP; CagriSema adds amylin signalling — two distinct pathways on top of GLP-1. Community consensus has not settled; confessions from those who have tried both are rare.